argenex (ARGX) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of argenex (NASDAQ: ARGX) recently:

• 8/31/2026 – argenex had its price target raised by Morgan Stanley from $1,230.00 to $1,250.00. They now have an “overweight” rating on the stock.
• 8/29/2026 – argenex was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/26/2026 – argenex had its price target raised by Wells Fargo & Company from $1,350.00 to $1,415.00. They now have an “overweight” rating on the stock.
• 8/26/2026 – argenex was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $1,400.00 price target on the stock, up from $960.00.
• 8/24/2026 – argenex was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”.
• 8/18/2026 – argenex had its price target raised by Truist Financial Corporation from $1,030.00 to $1,095.00. They now have a “buy” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Morgan Stanley from $1,200.00 to $1,230.00. They now have an “overweight” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Royal Bank Of Canada from $1,025.00 to $1,100.00. They now have an “outperform” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Wedbush from $1,050.00 to $1,150.00. They now have an “outperform” rating on the stock.
• 8/18/2026 – argenex had its price target raised by Citizens Jmp from $932.00 to $1,200.00. They now have a “market outperform” rating on the stock.
• 8/18/2026 – argenex had its price target raised by HC Wainwright from $940.00 to $1,202.00. They now have a “buy” rating on the stock.
• 8/17/2026 – argenex had its price target raised by Piper Sandler from $1,075.00 to $1,215.00. They now have an “overweight” rating on the stock.
• 8/15/2026 – argenex was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/4/2026 – argenex is now covered by Guggenheim. They set a “buy” rating and a $1,185.00 price target on the stock.
• 7/28/2026 – argenex had its price target raised by Wedbush from $1,000.00 to $1,050.00. They now have an “outperform” rating on the stock.
• 7/27/2026 – argenex had its price target raised by Robert W. Baird from $867.00 to $932.00. They now have a “neutral” rating on the stock.
• 7/25/2026 – argenex was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/24/2026 – argenex had its price target raised by Oppenheimer Holdings, Inc. from $1,014.00 to $1,037.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – argenex had its price target raised by Royal Bank Of Canada from $945.00 to $1,025.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – argenex had its price target raised by Guggenheim from $1,135.00 to $1,185.00. They now have a “buy” rating on the stock.
• 7/24/2026 – argenex had its price target lowered by Citizens Jmp from $944.00 to $932.00. They now have a “market outperform” rating on the stock.
• 7/23/2026 – argenex was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 7/21/2026 – argenex had its price target raised by Citigroup Inc. from $1,152.00 to $1,182.00. They now have a “buy” rating on the stock.
• 7/7/2026 – argenex had its price target raised by Royal Bank Of Canada from $890.00 to $945.00. They now have an “outperform” rating on the stock.
• 7/6/2026 – argenex was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 7/2/2026 – argenex had its price target raised by Bank of America Corporation from $1,016.00 to $1,088.00. They now have a “buy” rating on the stock.

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.